Inducible T‐Cell Co‐Stimulator ( <scp>ICOS</scp> ) and <scp>ICOS</scp> Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System
Biomarker-driven approaches will be important to individualize therapy and ascertain which cancer patients will derive the greatest benefit from ICOS-directed combination therapy approaches.
Authors
- Daisuke Nishizaki (ORCID: https://orcid.org/0000-0002-6746-3224)
- Jeffrey M. Conroy (ORCID: https://orcid.org/0000-0003-1764-9706)
- Mina Nikanjam (ORCID: https://orcid.org/0000-0001-7052-6348)
- R. Kurzrock
- Hirotaka Miyashita (ORCID: https://orcid.org/0000-0002-0433-9779)
- Sarabjot Pabla (ORCID: https://orcid.org/0000-0002-7746-9144)
- Mary Nesline (ORCID: https://orcid.org/0000-0003-0523-4597)
- Heidi Ko (ORCID: https://orcid.org/0000-0002-7247-9175)
- Shumei Kato
- Aung Naing
Institutions
- Dartmouth College (US)
- The University of Texas MD Anderson Cancer Center (US)
- Medical College of Wisconsin (US)
- LabCorp (United States) (US)
- University of California San Diego (US)
- Southeast Clinical Oncology Research Consortium (US)
- Dartmouth Psychiatric Research Center (US)
- Medical College of Wisconsin Cancer Center
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1002/cam4.71467
- Citations
- 2
- Primary Topic
- Microbial metabolism and enzyme function
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Pfizer
- AstraZeneca
- Medpace
- Regeneron Pharmaceuticals
- Incyte
- Actuate Therapeutics
- Eisai
- Grifols
- National Institutes of Health
- Genentech
- Chugai Pharmaceutical
- Foundation Medicine
- National Cancer Institute